1. Commensal bacterial metabolites may strengthen the effect of anti-IL6 treatment for COVID-19
- Author
-
Luis Vitetta and Jiezhong Chen
- Subjects
2019-20 coronavirus outbreak ,IL-6R antagonist ,Coronavirus disease 2019 (COVID-19) ,SARS-CoV-2 ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,COVID-19 ,Butyrate ,Tocilizumab ,Antibodies, Monoclonal, Humanized ,Microbiology ,Coronavirus ,Treatment ,chemistry.chemical_compound ,Cytokine release syndrome ,chemistry ,Full Length Article ,Humans ,Immunology and Allergy ,Medicine ,business - Abstract
Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications., Graphical abstract Unlabelled Image, Highlights • The lack of RCT forced the use of potential treatments in an emergency context, and results are of particular relevance. • Early administration of IL6-R antagonist tocilizumab, may be an effective and safe treatment for moderate to severe SARS-CoV2 positive patients. • Tocilizumab may prevent irreversible cytokine release syndrome CRS. • Tocilizumab reduced intubation, ICU admission, and decreased the risk of mortality. • Future prospective RCT will give answer about which are the first line drugs to treat COVID-19.
- Published
- 2021
- Full Text
- View/download PDF